Catalog Advanced Search

Search by Category
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Contains 6 Product(s)

    This webinar series debuted in June 2021, highlighting new developments and cutting edge research in the field of CAR T. Recordings and slides of these webinars

    This webinar series debuted in June 2021, highlighting new developments and cutting edge research in the field of CAR T. Recordings and slides from the live webinars have been posted here for your easy viewing.

  • Contains 1 Component(s) Includes a Live Web Event on 01/20/2022 at 2:30 PM (EST)

    Join us on January 20, 2022 at 1:30 PM CT for the sixth and final installment of the ASTCT CAR T Webinar Series. This webinar will feature presentations from Dr. Debora Barton, Dr. Michael Caligiuri, and Dr. Eric Smith highlighting novel therapies and opportunities for the future directions of the field.

    Join us on January 20, 2022 at 1:30 PM CT for the sixth and final installment of the ASTCT CAR T Webinar Series. This webinar will feature presentations from Dr. Debora Barton, Dr. Michael Caligiuri, and Dr. Eric Smith highlighting novel therapies and opportunities for the future directions of the field. The presentations will be followed by a robust panel discussion led by Dr. Yan Leyfman and Dr. Armin Ghobadi.

  • Contains 3 Component(s) Includes a Live Web Event on 01/19/2022 at 1:00 PM (EST)

    Join us on January 19, 2022 at 12:00 PM CT for the next session of the expanded ASTCT Journal Club. This webinar will consist of two, 30-minute journal club presentations, which included 20 min for presentation and 10 min for discussion/Q and A.

    ASTCT January Journal Club Session

    Join us on January 19, 2022 at 12:00 PM CT for the next session of the expanded ASTCT Journal Club. This webinar will consist of two, 30-minute journal club presentations, which included 20 min for presentation and 10 min for discussion/Q and A.

    Presenters & Articles

    Dr. Amanda Johnson, Oregon Health & Sciences University

    Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

    Dr. Sayeef Mirza, Yale University

    CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial


  • Contains 7 Component(s)

    The ASTCT and WBMT webinar, Allogeneic Stem Cell Transplantation for Non-malignant Disorders: a Global Perspective, was presented on November 24th, 2021 from 6 AM - 7:30 AM CST.

    This webinar was organized by the Worldwide Network for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. The webinar provides an overview of the current knowledge and best practices for allogeneic stem cell transplantation (HCT) in patients with non-malignant disorders (NMD). 

    Program and Speakers: 

    - Welcome and Introduction: Yoshihisa Kodera and Domiano Rondelli


    - The Global State of HCT for NMD: Results of the WBMT Survey

                    Dietger Niederwieser - University of Leipzig, Germany


    - What should we consider about the donor when performing HCT in NMD?

                    Nina Worel - Medical University of Vienna, Austria

     


    - HCT in Bone marrow failure syndromes: severe aplastic anemia-Fanconi anemia

                    Nada Hamad - St Vincent´s Hospital, Sydney, Australia

     


    - HCT in Thalassemia

                    Vikram Mathews - Christian Medical College, Vellore, India

     


    - HCT in sickle cell disease

                    Selim Corbacioglu - University of Regensburg, Germany

     


    - HCT for primary immunodeficiencies

                    Carmem Bonfim - Hospital Pequeno Principe, Curitiba, Brazil


    - Panel discussion: “Sharing experiences from different world regions” 

  • Contains 1 Component(s)

    In this 20 minute module, Dr. Kirsten Williams from Children’s Healthcare of Atlanta reviews the most recent NIH consensus statements on diagnosis, staging, and response scoring of chronic graft-versus-host disease after hematopoietic stem cell transplant. The current focus in this area is early detection. This is a first in a series of three modules addressing unmet needs in chronic graft versus host disease.

    In this 20 minute module, Dr. Kirsten Williams from Children’s Healthcare of Atlanta reviews the most recent NIH consensus statements on diagnosis, staging, and response scoring of chronic graft-versus-host disease after hematopoietic stem cell transplant.  The current focus in this area is early detection. This is a first in a series of three modules addressing unmet needs in chronic graft versus host disease.

    Activity Title: Diagnosing and Assessing Chronic Graft-versus-Host Disease

    Topic: cGVHD

    Accreditation Type: AMA PRA Category 1 Credit(s)™ 

    Release Date: 12/2021

    Expiration Date: 12/2022

    Estimated Time to Complete Activity: 20 mins

    LEARNING OBJECTIVES
    Upon completion of the activity, participants should be able to:
    • Discuss recent and ongoing updates to guidelines and consensus statements for cGvHD

    FACULTY 
    Steven Pavletic, MD, MS
    Head, Graft-Versus-Host Disease and Late Effects Section
    Center for Cancer Research
    National Institute of Health
    Bethesda, MD

    Kirk Schultz, MD
    Investigator, Michael Cuccione Childhood Cancer Research Program
    Director, Michael Cuccione Childhood Cancer Research Program
    British Columbia Children’s Hospital
    Professor, Division of Hematology and Oncology and Department of Pediatrics
    University of British Columbia
    Vancouver, BC

    Kirsten Williams, MD
    Pediatric Hematologist/Oncologist, Aflac Cancer & Blood Disorders Center
    Children’s Healthcare of Atlanta
    Associate Professor of Pediatrics
    Emory University School of Medicine
    Atlanta, GA

    Olaf Penack, MD
    Department of Hematology, Oncology and Tumor Immunology
    Charité-Universitätsmedizin Berlin
    Berlin, Germany 

    METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT
    Technical Requirements: http://www.francefoundation.co...
    1. There are no fees for participating in and receiving credit for this activity 
    2. Review the activity objectives and CME/CE information
    3. Complete the CME/CE activity 
    4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
    5. Complete the CME/CE evaluation/attestation form. This form provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
    6. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

    ACCREDITED PROVIDER
    This activity is provided by The France Foundation and produced in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT).

    TARGET AUDIENCE
    This activity is intended for oncologists, hematologists, physician assistants, nurse practitioners, pharmacists, and other health care professionals involved in treating and managing patients with cGVHD.

    STATEMENT OF NEED
    A significant number of patients—some 30% to 70%—will develop cGvHD after allo-HSCT. It typically manifests during the first year after transplantation, but it can occur several years later. cGvHD is also the leading cause of non-relapse mortality in allo-HSCT patients. The earliest possible diagnosis is critical, as once patients meet diagnostic criteria for GvHD, they may have already developed significant morbidity and possibly even irreversible organ damage. Guidelines and consensus statements from the National Institutes of Health (National Cancer Institute; NIH/NCI), the European Society for Blood and Marrow Transplantation (ESBMT), and the National Comprehensive Cancer Network (NCCN) exist to help diagnose, stage, and manage cGvHD. Unfortunately, uptake and use of guidelines have been inconsistent and variable.

    ACCREDITATION STATEMENT  
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and American Society for Transplantation and Cellular Therapy. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

    CREDIT DESIGNATION
    Physicians
    The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    DISCLOSURE POLICY
    In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

    Activity Staff Disclosures 
    The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

    The planners, reviewers, staff, or other members at American Society for Transplantation and Cellular Therapy who control content have no relevant financial relationships to disclose.

    Faculty Disclosures - Content Creators 
    The faculty listed below report that they have no relevant financial relationships to disclose:
    • Kirsten Williams, MD
    • Kirk Schultz, MD

    The following faculty report that they have relevant financial relationships to disclose: 
    • Olaf Penack, MD, has done non-CE consulting for Jazz, Gilead, MSD, Omeros, Priothera, Shionogi, and SOBI. He has served on the speaker’s bureau for Astellas, Gilead, Jazz, MSD, Neovii Biotech, Novartis, Pfizer, and Therakos. He has also done contract research for Gilead, Incyte, Jazz, Neovii Biotech, and Takeda.
    • Steven Pavletic, MD, MS has done contract research for Kadmon, Eli Lilly, and Pharmacyclins.

    DISCLOSURE OF UNLABELED USE
    TFF and ASTCT require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information. 

    COMMERCIAL SUPPORT ACKNOWLEDGMENT
    This activity is supported by an educational grant from Incyte.

    DISCLAIMER 
    The France Foundation and American Society for Transplantation and Cellular Therapy present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, American Society for Transplantation and Cellular Therapy, and the commercial supporter(s) assume no liability for the information herein.

    COPYRIGHT INFORMATION
    Copyright © 2021 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions: 
    • The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered. 
    • Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein), without The France Foundation's prior written permission 

    PRIVACY POLICY
    The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except when such information is required for reporting purposes to the ACCME.

    The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

    Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy. 

    CONTACT INFORMATION
    If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

  • Contains 4 Product(s)

    These are all the recordings and slides of the four sessions from the live virtual event the 2021 AcCELLerate Forum: Creating a Sustainable Ecosystem of Cell and Gene Therapy, hosted by ASTCT™, the CIBMTR® and the National Marrow Donor Program®(NMDP)/Be The Match®. Purchase this package to get access to all four sessions at a discounted rate!

    These are the recordings and slides of the four sessions from the live virtual event the 2021 AcCELLerate Forum: Creating a Sustainable Ecosystem of Cell and Gene Therapy, hosted by ASTCT™, the CIBMTR® and the National Marrow Donor Program®(NMDP)/Be The Match®. This live event took place on November 18 and 19, 2021. This two-day, virtual workshop offered providers, payers, government agencies, and industry involved in the field of cell and gene therapy increased educational and advocacy opportunities. This new workshop featured educational sessions bridging the gap among stakeholders, and identify ongoing needs and opportunities in the field for advocacy, measurement of value and impact, and sustainability.


    Purchase this package to get access to all four sessions at a discounted rate! Individuals who registered to attend this event live are eligible to receive access to these recordings free of charge. Please email info@astct.org to receive your discount.

  • Contains 2 Component(s)

    This is the recording and slides of the session presented live at the 2021 AcCELLerate Forum: Creating a Sustainable Ecosystem of Cell and Gene Therapy. The event aired live on Friday, November 19, 2021.

    This is the recording and slides of the session presented live at the 2021 AcCELLerate Forum: Creating a Sustainable Ecosystem of Cell and Gene Therapy. The event aired live on Friday, November 19, 2021. Topics include:

    • Sustainability of the field
    • Transition from auto products to off the shelf products
    • Contemporary look at the field and the pipeline
    • Solid tumors as indications
    • CAR, TCR, and TILs in the commercial setting

    Session Chairs: Dr. Saar Gill, MD, PhD (University of Pennsylvania), Dr. Rebecca Gardner, MD (Seattle Children’s Hospital and Fred Hutchinson Cancer Research Center), and Dr. Steve Devine, MD (NMDP/Be The Match and Be The Match BioTherapies)

    Speakers: Dr. Matthew Frigault, MD (Massachusetts General Hospital), Dr. Rimas Orentas, PhD (Seattle Children's Hospital), Dr. Mark Frattini, MD, PhD (Cellectis), and Dr. Ginna Laport, MD (Genentech)

  • Contains 1 Component(s)

    The Pharmacy SIG Online Journal Club session will be presented on November 10th, 2021 at 2 pm CT/3 pm ET.

    Presenters & Articles

    Lindsey Catlin, PharmD
    PGY2 Oncology Resident
    St Luke's Health System
    Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission

    Jack Malespini, PharmD
    PGY2 Oncology Pharmacy Resident
    Massachusetts General Hospital
    jmalespini@mgh.harvard.edu 
    Post-transplant Cyclophosphamide Versus Thymoglobulin in HLA Mismatched Unrelated Donor Transplant for Acute Myelogenous Leukemia and Myelodysplastic Syndrome

     

    Session Learning Objectives:

    Upon completion of the activity, participants should be able to:

    - Discuss recent BMT pharmacy studies and their applications to current practice.
    - Evaluate the role of autologous transplant versus treatment with chimeric antigen receptor t-cell therapy in patients with relapsed DLBCL in partial remission.
    - Compare and contrast the utility of post-transplant cyclophosphamide (PTcy) versus thymoglobulin for graft versus host disease (GVHD) prophylaxis in mismatched unrelated donor (MMUD) transplantation.

    This activity is jointly provided by The France Foundation and ASTCT. The France Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and will award 1.0 CEU to pharmacists who complete the activity, complete the registration and evaluation forms, and successfully pass a post-test (>75%).

    Full CE information, including presenter disclosures and accreditation information, can be found in the Handouts tab or directly downloaded by clicking here.

  • Contains 1 Component(s)

    The Pharmacy HCT Core Topics Live Session will be presented on November 3rd, 2021 at 2:30 pm CT / 3:30 pm ET.

    ASTCT Pharmacy HCT Core Topics Connection - Live

    This interactive live session will give learners the opportunity to talk with the Pharmacy SIG HCT Core Topics Connection presenters live. Participants will rotate to each topic for a follow-up discussion on each of the four modules.

    Speakers and Topics:

    - Graft-versus-Host Disease (GVHD) – Presented by Zahra Mahmoudjafari, PharmD, BCOP, DPLA and Rebecca Gonzalez, PharmD, BCOP

    - Infection Prophylaxis in HCT – Presented by Arpita Shah Gandhi, PharmD, BCOP and Dennis Marjoncu, PharmD, BCOP

    - Chimeric Antigen Receptor (CAR) T-cell Therapies – Presented by Katie S. Gatwood, PharmD, BCOP and May T. Aziz, PharmD, BCOP

    - Conditioning Regimens Used in Hematopoietic Cell Transplantation – Presented by Binni Kunvarjee, PharmD, BCOP, Maggie Nelson, PharmD, BCOP, and Vinita Pai, PharmD, MS

  • Contains 2 Component(s)

    This webinar aired live on October 28, 2021, as the fifth installment of the CAR T Webinar Series from ASTCT. This webinar featured presentations highlighting the key areas of logistics for operating CAR T programs, including reimbursement structure, inpatient vs. outpatient settings, programs in developing countries, data management, and clinical trials. There was also a robust panel discussion on these topics moderated by Dr. Antonio Macedo.

    This webinar aired live on October 28, 2021, as the fifth installment of the CAR T Webinar Series from ASTCT. This webinar featured presentations from Dr. Renato Cunha, Dr. Katie Gatwood, and Dr. Zahra Mahmoudjafari highlighting the key areas of logistics for operating CAR T programs, including reimbursement structure, inpatient vs. outpatient settings, programs in developing countries, data management, and clinical trials. There was also a robust panel discussion on these topics moderated by Dr. Antonio Macedo.


    Speakers:

    Dr. Katie Gatwood is a board-certified oncology pharmacist practicing as a Clinical Pharmacist Specialist in Adult Stem Cell Transplant and Cellular Therapy at Vanderbilt University Medical Center in Nashville, TN. She is passionate about clinical research and education, and has authored several publications and textbook chapters related to management of cellular therapy patients, including chimeric antigen receptor T-cell therapy. She is an active member of the American Society for Transplantation and Cellular Therapy (ASTCT) and was the recipient of the 2021 ASTCT Pharmacy SIG New Practitioner Award.

    Dr. Zahra Mahmoudjafari is a board certified oncology pharmacist. She earned her doctorate of pharmacy at the University of Missouri-Kansas City and completed her pharmacy practice residency at The Ohio State University Medical Center in Columbus, Ohio and her oncology specialty residency the Huntsman Cancer Institute in Salt Lake City, Utah. She currently works as a Clinical Pharmacy Manager for Hematology/Blood and Marrow Transplant and Cellular Therapeutics at the University of Kansas Health System. She also currently serves as the residency program director for the PGY2 Oncology residency program. She maintains active organizational involvement with the Hematology Oncology Pharmacists Association (HOPA), Advanced Topics for Oncology Pharmacy Professionals (ATOPP) as well as the American Society for Transplantation and Cellular Therapeutics (ASTCT) where she had served as chair of the Pharmacy Special Interest Group and participates in committees such as the Practice Guidelines Committee, Government Relations Committee and Content Committee.

    Dr. Renato Cunha graduated in Medicine from the Faculty of Medicine of the Federal University of Uberlândia, and was a Clinical Fellow in Hematology (2009), and Bone Marrow Transplantation and Cell Therapy (2010) at the Clinical Hospital of Ribeirão Preto Medical School of University of São Paulo. Postdoctoral Fellowship in Bone Marrow Transplantation and Cell Therapy at the National Cancer Institute (ETIBNCI/NHI) in Bethesda, USA (2015-2018). Member of the Brazilian Society of Bone Marrow Transplant, the American College Physician, the American Society of Hematology, and the American Society for Transplantation and Cellular Therapy. Currently, Assistant Professor of Medicine and Head of the Bone Marrow Transplantation and Cell Therapy Unit at the Clinical Hospital of Ribeirão Preto Medical School of the University of São Paulo (BMTU-HCFMRPUSP). In 2018 was awarded the ASH Global Research Award and in 2019, performed the first car t-cell treatment in Latin America in Ribeirão Preto, Brazil. In 2021, coordinate the first Brazilian Consensus of Advanced Cellular Therapy of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy.